Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
Publication date
2017-11
Authors
Verheijen, Remy B.
Yu, Huixin
Schellens, Johannes
Beijnen, Jos
Steeghs, Neeltje
Huitema, Alwin D R
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
Abstract
Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable and clear relationships exist between exposure and treatment outcomes, fixed dosing is still standard practice. This review aims to summarize the available clinical pharmacokinetic and pharmacodynamic data into practical guidelines for individualized dosing of KIs through therapeutic drug monitoring (TDM). Additionally, we provide an overview of prospective TDM trials and discuss the future steps needed for further implementation of TDM of KIs.
Keywords
Dose-Response Relationship, Drug, Drug Monitoring, Humans, Medical Oncology, Neoplasms, Practice Guidelines as Topic, Prospective Studies, Protein Kinase Inhibitors
Citation
Verheijen, R B, Yu, H, Schellens, J H M, Beijnen, J H, Steeghs, N & Huitema, A D R 2017, 'Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology', Clinical Pharmacology and Therapeutics, vol. 102, no. 5, pp. 765-776. https://doi.org/10.1002/cpt.787